Research
Hormonal
Pharmacological interventions, specifically GLP-1 receptor agonists and SGLT2 inhibitors, reduce epicardial adipose tissue (EAT) volume and improve cardiovascular outcomes, often independent of weight loss.
If you have T2DM, obesity, or heart failure, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs can reduce the fat around your heart and improve your heart's function, sometimes even without significant weight loss.
GoodSupportsHIGH confidence
GLP-1 RAs have been consistently shown to rapidly reduce EAT (within 3 months) in a dose-dependent manner... SGLT2-i also demonstrates direct effects on EAT, reducing volume, inflammation, and diastolic dysfunction... independent of weight loss.
Why this rating
Supported by multiple randomized controlled trials and meta-analyses.
Source
Epicardial adipose tissue in coronary microvascular disease
Veronika Gašpárková et al. · American Heart Journal Plus Cardiology Research and Practice · 2026
DOI 10.1016/j.ahjo.2026.100734
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →